Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PEG-interferon alfa-2B may interfere with the growth of cancer cells. Combining temozolomide with PEG-interferon alfa-2B may be an effective treatment for advanced solid tumors. PURPOSE: Phase I trial to study the effectiveness of combining temozolomide and PEG-interferon alfa-2B in treating patients who have advanced solid tumors.

Key facts

Study ID

NCT00014261

Run by

Dartmouth-Hitchcock Medical Center

Starts

2000-10-01

Expected to finish

2002-11-01

Last updated by the study team

2018-03-30

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.